Zydus Lifesciences and Glenmark Pharmaceuticals have both received approvals from China’s National Medical Products Administration (NMPA) for their respective products. Zydus Lifesciences has been granted approval for Venlafaxine Extended-Release (ER) Capsules, 75 mg and 150 mg, which is the company’s first approval from the NMPA. The product will be manufactured at Zydus’ facility in Ahmedabad and is used to treat various conditions including Major Depressive Disorder, Generalised Anxiety Disorder, Social Anxiety Disorder, and Panic Disorder.
Glenmark Pharmaceuticals, on the other hand, has received approval for its Ryaltris compound nasal spray (GSP 301 NS) for the treatment of allergic rhinitis (AR) in adults and children. This approval is a significant milestone in Glenmark’s respiratory pipeline and was granted without any additional requests for supplementation. The commercialization of Ryaltris in China will be undertaken by Grand Pharmaceuticals Group under an exclusive licensing agreement.
The approval of these products is a significant development for both companies, as China is a key market for pharmaceutical companies. Glenmark Pharmaceuticals has stated that China is a priority market for the company, and they are committed to making their treatment accessible to patients and healthcare professionals in the country. The partnership with Grand Pharmaceuticals Group will enable Glenmark to achieve this goal.
The approvals are also a testament to the quality and efficacy of the products developed by Zydus Lifesciences and Glenmark Pharmaceuticals. The NMPA is a stringent regulatory authority, and the approval of these products demonstrates the companies’ ability to meet the highest standards of quality and safety. Overall, these approvals are a positive development for both companies and are expected to have a significant impact on their business in the Chinese market.